INTRODUCTION BONE BIOPSY

Double tetracycline labelling -DTCL
The first prerequisite for an informative bone biopsy is proper in vivo labeling with administration of specific, nontoxic, time-spaced bone markers before the biopsy. Antibiotics from the tetracycline family are used because they have spontaneous fluorescence and bind to actively forming bone surfaces. With labelling, the level of bone turnover and rate of bone formation can be determined, and possible mineralization abnormalities can be identified. A double labelling technique is optimal, although the schedule is somewhat more complicated than one prolonged single administration. For patients with normal renal function, dosages of tetracycline hydrochloride and Declomycin ® ‚ are usually 500 mg and 300 mg t.i.d., respectively. For patients with impaired renal function, dosages should be reduced to 500 mg and 300 mg b.i.d. In most cases, the first label is administered for 2 days followed by an 8-15 day free interval. Any time schedule with an interval shorter than 8 days lessens the distinction between labels, particularly in the case of a mineralization defect. Any interval longer than 15 days may artificially increase the number of single labels because the number of forming sites being completed or started will possibly increase. During the 2-4 days after the free interval, the patient takes a second course of antibiotics. Bone biopsy is then performed 4-6 days after the last administration of tetracycline. During this delay, the tetracycline becomes slightly buried within mineralized osteoid and does not leach out. In an emergency, labelling can be shortened to a 1-day-on, 6-days-off and 1-day-on schedule with a single dose of oral tetracycline per day (1.0-1.5 g of tetracycline or 600-900 mg of Declomycin ® ). Gastrointestinal side effects may be greater with this approach. Using two labels with different colors assures accurate assessment of the mineralization rate. Tetracycline hydrochloride has a light yellow and demeclocycline hydrochloride (Declomycin ® ) a yellow-orange fluorescence. With the use of only one type of tetracycline, the two labels can merge in states of low bone turnover and be unrecognizable as a double label.
Procedure
Bone biopsies can be performed with different instruments (e.g. Bordier-Meunier or Jamshidi needle) with an internal diameter from 5 to 7 mm. The biopsy set consists of 4 instruments ( Fig. 1 ): a pointed obturator (A), a stabilizing sleeve with sharp serrated edges (B), a trephine biopsy needle with a flared handle (C) and a blunt metal rod to push the specimen out of the biopsy needle (D).
Most bone biopsies are performed under local anesthesia. The transiliac bone biopsy site is 2 cm posterior and 2 cm inferior to the anterior iliac spine (Fig. 2) . It is the generally preferred site owing to its accessibility and high bone turnover rate (13) . Iliac crest biopsies result in cores with a single cortical surface, while transiliac biopsies yield cores with two cortical surfaces (13) . The specimen is cut into two unequal cylinders. The largest part is used for histological examination and the smallest one is weighed immediately after sampling and used for bulk analysis by means of electrothermal atomic absorption (14, 15) . The different steps of the manual procedure are shown in Figure 3 .
The patient lies on a firm table in a supine position with the side at which biopsy is planned placed along the edge of the table. 1% lidocain solution is used for local infiltration of the skin after which a 1.5 cm incision is made using a scalpel. A pointed obturator (Fig. 3A) is introduced into the guide sleeve ( Fig. 3B ) and both are then inserted through the skin incision. The obturator is penetrated gently until its tip comes into contact with the ileum and the guide sleeve is advanced over the obturator until its serrated edge touches the ileum in a direction focused at the opposite shoulder. Then, the obturator is withdrawn, the trephine biopsy needle ( Fig. 3C ) is inserted into the guide sleeve and rotated manually with firm pressure until it cuts successively through all layers of the bone. After penetration of the inner cortical layer, the biopsy trephine should be rotated by 360 degrees about 20 times and then withdrawn, using a slow rotating motion. Removal of the biopsy from the trephine is accomplished by introducing the blunt extractor ( Fig. 3D ), gently pushing the specimen out (16) .
Complications from bone biopsies can include pain, hematoma, wound infection, and rarely neuropathy. However, studies show that horizontal or transiliac and vertical or superior biopsies of the anterior iliac crest result in very small morbidity and no mortality as a result of procedure (17) . The operator's experience is important in minimizing morbidity and in obtaining an adequate specimen. Use of recently developed techniques should further decrease any complications. Reports of pain range from none to moderate and rarely severe.
Qualitative and quantitative evaluations of the bone sample constitute the final steps in processing a bone biopsy. Qualitative assessment consists of such factors as the suitability of a biopsy for morphometric analysis, the amount of sample needed, where histologic structures should be measured, and what elements to evaluate. With quantitative evaluation, numerical values are assigned to the various elements constituting bone (18) . Potential differences between groups of patients or normal individuals or changes occurring after treatment can then be statistically evaluated.
Histomorphometric analysis is performed on 5 µm Goldner stained undecalcified, methylmetacr ylate embedded bone sections. For the detection and localization of aluminum the sections are stained with Aluminon ® . Unstained sections (7 µm) are used for the evaluation of tetracycline labels by fluorescence microscopy.
Semi-quantitative automated image analyzers (KS 400, VIDS II, IAS 2000) consisting of a color video-equipped computer which is linked to the microscope by a video camera are available, greatly reducing the time required to evaluate bone slides. Although they assess parameters of bone structure, they are not reliable in discriminating such elements as cellular details, detecting woven vs. lamellar bone, and recognizing erosion surface. However, complete automatic analysis of bone may be possible in the future, with improved video cameras, staining techniques, and computerized image-analysis capabilities. Nowadays, a more reliable morphometric evaluation should be expected from the specialized laboratories with an educated and experienced pathologist.
Bone biopsy
Based on histomorphometric findings, two main groups of renal bone disease can be classified: low (LTO) and high bone turnover (HTO) (5, 6) . Adynamic bone disease is characterized by a decreased number of osteoblasts and osteoclasts with a low bone formation rate (BFR) approaching zero values. The second type of LTO, osteomalacia (OM), has a superimposed mineralization defect producing a great amount of unmineralized osteoid. HTO bone disease includes mild and severe hyperparathyroid bone disease (HPTH) or osteitis fibrosa, characterized by an excessive number of osteoclasts and osteoblasts and a high rate of bone formation and resorption. Mixed uremic osteodystrophy (Mx) possesses the combined features of both HPTH and OM.
These standard histological techniques, however, have a number of unanswered questions regarding the altered biological activity or mechanisms of the diseases at a cellular level and regarding the understanding of the nature and the course of the diseases. The recent development of sensitive techniques including in situ hybridization (ISH) and in situ-reverse transcriptase-PCR (IS-RT-PCR) has introduced a new era in the study of various aspects of biomedical research in the field of renal osteodystrophy (19) .
Clinical application
Nephrologists must determine a patient's level of bone turnover to apply the correct therapy. Serum PTH levels measured with radioimmunometric assay are commonly used to assess bone turnover in dialyzed patients. Although these levels have been found to be more sensitive than the previously employed radioimmunoassay, at present there is no consensus regarding the serum level of PTH that reflects normal bone turnover in ESRD patients. Because bone biopsies provide a sensitive measurement of bone changes, they more accurately determine the type of renal osteodystrophy and can indicate potential aluminum and strontium accumulation in dialyzed patients. Bone biopsies also allow tailored therapeutic measures. The extent of aluminum deposits at the bone-osteoid interface and the level of bone turnover determine the optimal duration of chelating therapy. Hence, bone biopsies could be performed at an interval of 6-12 months, sufficient for recognition of the specific changes of bone remodeling and mineral metabolism. Although there is no preset limit for repeated bone biopsies, no more than two transiliac biopsies from each side, alternatively could be recommended.
If the biopsy shows no significant deposits of aluminum, the degree of bone turnover will help the practitioner to determine the route, aggressiveness, and length of calcitriol therapy. Severe hyperparathyroidism with marked bone marrow fibrosis is an indication for high doses of intravenous calcitriol if the calcium-phosphorus product can be controlled. Additionally, in cases with a high resistance to intravenous calcitriol at the needed massive doses, parathyroidectomy may be necessary. The severity of the effect of secondary hyperparathyroidism on bone may also indicate the extent of the post-parathyroidectomy "hungry bone syndrome" and allow preventive measures such as the preoperative injection of calcitriol. In patients with mild to moderate increase in bone turnover with or without mineralization defect, doses of intravenous or preoperative calcitriol and duration of therapy may be adjusted to avoid the development of ABD.
In the case of ABD, calcitriol therapy is not desirable because of the risk of inducing hypercalcemia, extraosseous calcifications and further suppression of parathyroid gland activity. Moreover, the use of a low calcium dialysate is recommended, as well as a lower daily intake of calcium in the diet, reducing also the treatment with calcium containing phosphate binding agents. However, the balance of calcium should be maintained very carefully, especially in old patients prone to osteoporosis and hip fracture. Here, calcium mineralization of the bone could not be possible without an activation of bone formation. Hence, the bone turnover should be increased throughout stimulation of the parathyroid gland activity first and then a positive calcium balance should be subsequently reinforced.
The patients with osteomalacia in the absence of aluminum and strontium accumulation should be treated with vitamin D and calcium supplements if needed.
A bone biopsy establishes the precise relationships between serum indices of calcium metabolism and bone lesions (20) . This enhances the inter pretation of longitudinal follow-up of noninvasive parameters while the patient is undergoing a particular therapy.
Present results
Our bone biopsy study in 84 ESRD patients revealed that 62% of a predialysis population had abnormal bone histology (5) . ABD was found to be the most frequent bone lesion observed in 23%, while HPTH (mild form) was diagnosed in only 9% of the patients. The majority of patients (38%) in our study presented with a normal bone histology. Hence, this finding differs considerably from the ROD spectra reported previously in non-dialysed renal failure patients where none of the patients was reported to have a normal bone histology (8, 10, 21) . Furthermore, our study revealed that serum calcium levels in 15 out of 19 (79%) patients with ABD appeared to be > 2.1 mmol/L; 4 of them were hypercalcemic >2.5 mmol/L and 12 (63%) presented with calcium x phosphorus product > 4.4 mmol/L (55 mg 2 /dL 2 ). These findings were in agreement with the afore-mentioned treatment for ABD patients.
A recent study with lanthanum carbonate as a new phosphate binder, has shown its safety and effectiveness in phosphate binding (22) . Additionally, in this multicentric, prospective, double bone biopsy study (baseline and after a year of treatment) we compared the effect of lanthanum carbonate (LC) and calcium carbonate (CC) on the evolution of renal osteodystrophy in dialysis patients. At the baseline biopsy 65% of the patients showed histomorphometric characteristics for mixed bone lesions and there was no patient diagnosed as having normal bone, which might be partially explained by different type of classification used for this evaluation. The one year bone biopsy showed that the treatment with lanthanum resulted in a normalization of the bone histomorphometric parameters in comparison with the baseline biopsy, while the patients treated with calcium carbonate showed an evolution towards low bone turnover at one-year follow-up in half of the patients. Concerning the bone related parameters, our between groups comparison showed borderline significance for iPTH at the end of the first year of treatment (p = 0.051). This could be explained by the sustained suppression of the parathyroid glands from significantly higher concentrations of serum calcium in the calcium carbonate treated group throughout the study (unpublished data).
Our experience on more than 150 transiliac bone biopsies showed no evidence of serious complications except for a few episodes of moderate pain at the site of bone biopsy. Hence, this method can be considered a safe and valuable diagnostic tool for the diagnosis of renal osteodystrophy.
CONCLUSIONS
Bone biopsies are presently more widely used for diagnosis and research than they have been in the past. However, traditional constraints continue to be perceived because of the procedure's invasiveness and cost, potential pain for the patient, delays between the biopsy and pathology reports, lack of specialized centers with expertise to interpret bone samples, lack of technical training, and limited understanding of the information provided by the results.
Efforts to minimize these constraints have included improved instrument design and biopsy techniques and more intensive and detailed training of clinicians and pathologists. Advances in bone sample processing have resulted in faster turnaround time between bone biopsy and availability of histologic results. This has enhanced the value of bone biopsy in routine patient care. Also, bone morphometrists now have a better understanding of bone biopsy results.
Alternatives to bone biopsy continue to be pursued. The search for noninvasive serum or bone markers that predict bone turnover, mineralization status, bone aluminum or strontium accumulation, and cellular abnormalities has resulted in improved methods to determine serum levels of various calcitropic hormones, isolation of proteins and enzymes from bone, and development of commercially available assays. However, these alternatives have not yet proven to be specific or sensitive enough to effectively replace the gold standard of bone biopsy.
